1. Juliusson G, Hoglund M, Karlsson K, Lofgren C, Mollgard L, Paul C, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. British journal of haematology. 2003;123(5):810-8.

2. Juliusson G, Billstrom R, Gruber A, Hellstrom-Lindberg E, Hoglunds M, Karlsson K, et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia. 2006;20(1):42-7.

3.Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-87.


4.Juliusson G, Karlsson K, Lazarevic V, Wahlin A, Brune M, Antunovic P, et al. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. Cancer. 2011;117(18):4238-46.

5.Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-34.


6.Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M, Swedish Acute Leukemia Registry G. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890-9.

7.Lazarevic V, Horstedt AS, Johansson B, Antunovic P, Billstrom R, Derolf A, et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood cancer journal. 2014;4:e188.

8.Hulegardh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf A, Mollgard L, Uggla B, Wennstrom L, Wahlin A, Hoglund M, Juliusson G, Stockelberg D, Lehmann S. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am j Hematol. 2015 May;94(5):419-23.

9.Lazarevic V, Horstedt AS, Johansson B, Antunovic P, Billstrom R, Derolf A, Lehmann S, Mollgard L, Peterson S, Stockelberg D, Uggla B, Vennstrom L, Wahlin A, Hoglund M, Juliusson G. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. Eur J Haematol. 2015 May;94(5):419-23.

10.Lazarevic V, Rosso A, Juliusson G, Antunovic P, Rangert-Derolf A, Lehmann S, et al. Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia. Am J Hematol. 2015;90(9):800-5.

11.Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf A, Garelius H, et al. Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden. Leukemia. 2017;31(3):728-31.

12.Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf AR, Deneberg S, et al. Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry. Eur J Haematol. 2017;98(5):493-500.

13.Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf A, Garelius H, Lazarevic V, et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia. 2017;31(6):1457-9.

14.Lazarevic VL, Bredberg A, Lorenz F, Ohlander E, Antunovic P, Cammenga J, et al. Acute myeloid leukemia in very old patients. Haematologica. 2018;103(12):e578-e80.

15.Angenendt L, Rollig C, Montesinos P, Martinez-Cuadron D, Barragan E, Garcia R, et al. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019;37(29):2632-42.

16.Juliusson G, Hagberg O, Lazarevic VL, Olander E, Antunovic P, Cammenga J, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134(18):1558-61.

17.Nilsson C, Hulegardh E, Garelius H, Mollgard L, Brune M, Wahlin A, et al. Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. Biol Blood Marrow Transplant. 2019;25(9):1770-8.

18.Derolf A, Juliusson G, Benson L, Floisand Y, Lazarevic V, Antunovic P, et al. Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor. Br J Haematol. 2020;188(1):187-91.

19. Osterroos A, Eriksson A, Antunovic P, Cammenga J, Deneberg S, Lazarevic V, et al. Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >/= 60 years. Br J Haematol. 2020.

20.Juliusson G, Hoglund M, Lehmann S. Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people. Haematologica 2020; 105(2)











Denna sidan använder cookies, genom att fortsätta godkänner du användandet av cookies.